The Future of Dermatology

thefutureofdermatology

Join Dr. Faranak Kamangar, MD, every week as she chats with various guests about the future of dermatology. Each week, Dr. Kamangar and her guests cover topics from psoriasis, to eczema, to skin care, to AI, and more. Whether you’re a doctor or a patient, these episodes provide valuable information about your skin and how to navigate the world of dermatology.

  1. Jun 2

    Episode 133: HS Treatment Pipeline Explosion: What's New & What's Next | The Future of Dermatology Podcast

    Summary: Hidradenitis Suppurativa (HS) is one of dermatology's most complex and underrecognized conditions and the treatment landscape is changing fast. In this episode, Dr. Faranak Kamangar sits down with Dr. Hadar Lev-tov, Associate Professor at the University of Miami, Director of the Wound Healing Fellowship, and Immediate Past President of the Hidradenitis Suppurativa Foundation, for a rapid-fire review of everything happening in the HS world right now. Dr. Lev-tov covers the currently approved therapies, the exciting drugs moving through Phase 3 trials, and the groundbreaking science linking microplastics to HS inflammation. He also shares his candid take on GLP-1s in HS management and what the future of dermatology looks like when treatments work so well that doctors can finally focus on the whole patient. Whether you're a resident just learning HS or a seasoned dermatologist trying to keep up with a fire-hose pipeline, this one is for you. Topics Covered: - Approved HS biologics: bimekizumab, secukinumab, adalimumab & biosimilars - Off-label use of infliximab (IV and subcutaneous) in severe HS - Phase 3 pipeline: remibrutinib, povorcitinib, sonelokimab (nanobodies) - CAR T-cell therapy and the possibility of curing inflammatory skin disease - Microplastics, nicastrin, and a landmark Nature Communications paper on HS - GLP-1s in HS: what we know, what we don't, and Dr. Levtov's clinical approach - The HS Foundation's research grants, HS Academy, wound care referral tool, and prior authorization templates - The future of dermatology as lifestyle medicine Resources Mentioned: - https://www.nature.com/articles/s41467-025-65789-7  - HS Foundation website & prior authorization templates: https://www.hs-foundation.org/ - HS Academy (free weekend for residents): https://www.hs-foundation.org/hs-academy - Integrative Dermatology Symposium: integrativedermatologysymposium.com - LearnSkin: learnskin.com This podcast is for educational purposes only and is not a substitute for professional medical advice. Always consult your healthcare provider. Key Takeaways: 1. Validate HS patients the moment they walk in. They've often been dismissed or bounced between providers for years. Simply saying "I understand what you're going through" builds trust immediately and makes the visit more productive. 2. The approved HS treatment arsenal is growing. Bimekizumab and secukinumab (IL-17 inhibitors) are now approved, and adalimumab — including biosimilars — remains a valuable option. Clinical experts are using biosimilars with confidence. 3. Subcutaneous infliximab is an emerging option. Available off-label in the US, new data from French centers shows a protocol: standard IV induction at weeks 0, 2, and 6, then switching to subcutaneous injections every two weeks at week 10 — but only once the patient is in strong remission. 4. Three major drugs are in or completing Phase 3 trials. Remibrutinib (BTK inhibitor, already approved for chronic spontaneous urticaria), povorcitinib (JAK1 inhibitor), and sonelokimab (a nanobody targeting IL-17A and IL-17F) are all reporting promising results and moving toward FDA application. 5. Nanobodies are a technology to watch. Derived from camelid antibody fragments, nanobodies like sonelokimab can be engineered to target multiple pathways simultaneously in a smaller, more modular molecule — expect to see them across dermatology. 6. Half-life extenders could mean one injection per year. Already emerging in psoriasis, these extended-dosing biologics are heading toward HS — a potential game-changer for patient adherence. 7. CAR T-cell therapy may one day cure inflammatory skin disease. Currently being studied in lupus and rheumatoid arthritis, the protocols are becoming more practical, and the technology is edging toward dermatology. 8. Microplastics may potentiate HS inflammation. A Nature Communications paper by Dr. Luis Garza (Hopkins) found that plastic-associated endocrine disruptors block nicastrin in fibroblasts, amplifying HS-related inflammation. This doesn't prove causation, but it reveals a meaningful environmental link — and highlights the underappreciated role of fibroblasts in HS scarring. 9. GLP-1s in HS: promising but not proven as monotherapy. There's no RCT yet. Dr. Levtov's clinical approach: stabilize HS with a biologic first, then consider adding a GLP-1 as part of a comprehensive plan that includes diet and resistance training. He has seen outcomes go both ways. 10. The HS Foundation is an underutilized resource. Their website offers a clinic finder, wound care referral service, prior authorization templates (one-click Word documents), research grants, the HS Academy (free, all-expenses-paid weekend for residents), and career development awards in partnership with the Dermatology Foundation. Chapters: 0:00 – Introduction & Dr. Lev-tov's Background 0:49 – The #1 Clinical Tip for Seeing HS Patients 1:44 – Approved HS Treatments: IL-17 Inhibitors, Adalimumab & Biosimilars 2:40 – Off-Label Infliximab: IV and the New Subcutaneous Protocol 4:21 – Phase 3 Pipeline: Remibrutinib, Povorcitinib & Sonelokimab (Nanobodies) 6:00 – Half-Life Extenders & One-Injection-Per-Year Future 7:01 – CAR T-Cell Therapy: Could We Cure Inflammatory Skin Disease? 7:36 – Research Funding & HS Foundation Grants 8:43 – HS Foundation Tools: Prior Auth Templates, Clinic Finder & HS Academy 10:15 – Microplastics, Nicastrin & the Nature Communications Paper 13:22 – What This Means for Fibroblasts and HS Scarring 14:20 – Celebrating Dermatology Science & Clinician-Scientists 15:32 – GLP-1s & HS: What's the Evidence? 17:18 – Dr. Lev-tov's Clinical Approach to GLP-1 Requests 19:06 – The Future of Dermatology: Becoming Lifestyle Doctors 21:28 – The Integrative Dermatology Symposium & LearnSkin Certificate Program 22:50 – Closing Remarks

    23 min
  2. May 19

    Episode 132: Behind the Scenes: Podcast Milestones, SF Derm 2026, & Derm GPT | The Future of Dermatology Podcast

    📋 Summary: In this special behind-the-scenes episode, Dr. Faranak Kamangar welcomes podcast producer Steph Cullen on camera for the first time in two years. Together they reflect on over three years of building the Future of Dermatology podcast, now a top dermatology-facing podcast with 130+ episodes, 40,000+ total plays across all platforms, and over 700 downloads a month, all achieved with zero paid marketing. Dr. Kamangar shares exciting updates happening this summer, including the opening of her new Palo Alto practice in August, the upcoming SF Derm 2026 conference (August 28–30 at the Four Seasons Silicon Valley in Palo Alto), and the explosive growth of DermGPT, her AI tool built specifically for dermatologists and derm providers. She also celebrates her recognition on the Inc. Female Founders 500 list for her work in health tech AI. The conversation covers what makes this podcast stand out - a steadfast commitment to evidence-based, science-forward dermatology content - and looks ahead to the future, including expanding the guest roster geographically, a possible move into short-form content, and a growing focus on AI in dermatology. Whether you're a longtime listener or just discovering the show, this episode is a candid, energetic look at what's been built and what's coming next. Register for SF Derm 2026! https://www.sfderm.org/ ✅ Key Takeaways: 1. The podcast has grown organically to become a top dermatology-facing show. With 130+ episodes, 40,000+ total plays, and over 700 monthly downloads across Spotify, Apple, and YouTube - all without paid promotion or leaderboard platforms - the Future of Dermatology has become one of the most listened-to dermatology podcasts available. 2. Staying science-first has been the secret to longevity. Dr. Kamangar and Steph emphasize that resisting the temptation to chase trending or sensational topics in favor of solid, evidence-based science is what built a loyal, engaged audience of dermatologists, providers, and interested listeners. 3. SF Derm 2026 is shaping up to be the biggest one yet. The conference runs August 28–30 at the Four Seasons Silicon Valley in Palo Alto. Highlights include a tech-forward AI and derm panel featuring physicians from Stanford and Harvard, a metabolic and HS/vulvar disease panel, a hormones talk by an OB-GYN, grand rounds, resident jeopardy, and a Saturday night "1001 Nights" themed party. 4. DermGPT has reached over 23,000 dermatology providers - with more than 5,000 using it regularly - built by a team of just three people with no marketing budget. Dr. Kamangar built this tool out of a recognized need: dermatology makes up less than 2% of the house of medicine, making it an overlooked target for health tech development, yet burnout from administrative burden is high. 5. AI is about giving doctors time back, not replacing them. The episode makes a compelling case that AI tools like DermGPT are most valuable not for replacing clinical judgment, but for reducing "pajama time" - the hours physicians spend on documentation and inbox management after hours - so they can focus on the work they're most passionate about. 6. The podcast has begun influencing larger media. A patient episode on atopic dermatitis caught the attention of Time Health, who reached out to feature the guest. This kind of organic mainstream crossover validates the show's mission to bring credible dermatology science to wider audiences. 7. There are dermatology deserts across the U.S. The episode briefly touches on geographic disparities in dermatology access, with Steph noting the growing need for telehealth solutions. Dr. Kamangar acknowledges the podcast's current West Coast bias and invites listeners to recommend guests from underrepresented regions. 🕐 Chapters: 00:00:01 — Welcome & Introduction 00:00:54 — Meet Steph Cullen: The Face Behind the Scenes 00:02:33 — Three Years, 130+ Episodes & 40,000 Plays 00:04:53 — Why Staying Science-Forward Has Paid Off 00:07:15 — SF Derm 2026: Dates, Venue & What to Expect 00:09:54 — The SF Derm Experience: Education, Energy & the Party 00:11:10 — AI & Derm Tech Panel Preview 00:13:27 — The Magic of In-Person Podcast Recording at SF Derm 00:14:44 — When the Podcast Caught Time Health's Attention 00:15:39 — DermGPT & the Inc. Female Founders 500 Recognition 00:18:37 — AI's True Role: Giving Doctors Their Time Back 00:22:06 — The Future of the Podcast: More Guests, More Geography 00:23:36 — Closing Thoughts & What's Coming This Summer

    25 min
  3. May 5

    Episode 131: HS Updates, Prior Auth Reform & CA Legislation in Dermatology ft. Dr. Haley Naik | The Future of Dermatology Podcast

    Summary: In this episode of the Future of Dermatology podcast, host Dr. Faranak Kamangar sits down with Dr. Haley Naik, board-certified dermatologist, professor at UCSF, and Stanford and Harvard-trained expert, for a timely and eye-opening conversation on two major fronts: the rapidly evolving treatment landscape for Hidradenitis Suppurativa (HS) and the critical California state legislation that could reshape how dermatologists practice and how patients access care. Dr. Naik opens with exciting updates in the HS space, including the three currently FDA-approved therapies and two promising agents anticipated to cross the finish line by 2027. She also shares a major advocacy win: HS has been designated a highlighted research topic by the NIH across three institutes, opening a one-year funding window starting April 7, 2026 that researchers should act on now. The conversation then dives deep into the broken prior authorization system, with striking data points: 25% of dermatology visits require prior auth, 75% of denial letters have no listed decision maker, and the average dermatology practice spends $40,000 per year staffing for prior authorizations. Against this backdrop, Dr. Naik breaks down three California bills - two to support and one to oppose - that directly affect how dermatologists can care for their patients. Whether you're a dermatologist, researcher, or patient advocate, this episode is packed with actionable information, from NIH grant deadlines to how to contact your state representative before late June voting deadlines. Learn more and take action: AB539 (prior authorization reform): https://legiscan.com/CA/bill/AB539/2025 SB895 (California Science and Health Research Bond Act): https://lnkd.in/gTjXXxtU Find your California representative to advocate for these bills: https://findyourrep.legislature.ca.gov/ Information about the May 4th Rally for California Science: https://www.fundcascience.org/rally 🔔 Subscribe for more episodes on the latest in dermatology science, innovation, and advocacy. ⚠️ This podcast is for educational purposes only and does not constitute medical advice. Always consult your healthcare provider. Key Takeaways: 1. Three FDA-Approved HS Therapies Now Available Adalimumab, Secukinumab, and Bimzelx (bimekizumab) are currently FDA-approved for Hidradenitis Suppurativa, giving clinicians meaningful treatment options that didn't exist before 2015. 2. Two More HS Therapies Expected by 2027 Povorcitinib (a JAK1 inhibitor by Incyte) and an IL-17A/F nanobody by Moonlake Therapeutics are both anticipated to receive approval in the coming years, with over 50 therapies currently in the HS pipeline. 3. NIH Has Designated HS a Highlighted Funding Topic - Act Before April 2027 HS has been named a highlighted research topic across three NIH institutes. This designation runs from April 7, 2026 through April 2027. Researchers interested in HS funding must submit applications within this one-year window. 4. The Prior Authorization System Is Widely Acknowledged as Broken Even the Blue Shield CEO publicly admitted the prior auth process is broken. The insurance industry issued a voluntary streamlining pledge in summer 2025. Key pain points include: step therapy requirements, peer-to-peer reviews often conducted by non-physicians, no identified decision maker on 75% of denial letters, and reauthorization periods as short as three months. 5. AB 539 Would Extend Prior Auth Approvals to One Full Year Currently, prior authorizations for some medications last as little as three months, forcing practices to repeatedly restart the paperwork process and creating dangerous gaps in patient care. AB 539 would require approved prior authorizations to be maintained for one year (or the full treatment course if shorter). This is especially impactful for HS patients who already face a 7–10 year diagnostic delay. 6. AB 2000 Would Ban Mid-Year Formulary Changes If a patient is doing well on a medication, insurers could currently remove that drug from formulary mid-year, forcing patients back through step therapy and increasing out-of-pocket costs. AB 2000 would prohibit these mid-year changes, protecting both patient stability and physician treatment decisions. 7. SB 1094 Would Expand Pharmacist Biosimilar Substitution Authority - and Is Opposed Under current California law, pharmacists can only substitute a biologic with an FDA-designated "interchangeable" biosimilar, which requires extensive switching data. SB 1094 would allow substitution with any biosimilar, potentially without physician notification. The California Medical Association (CMA) opposes this bill due to patient safety concerns, as it removes clinical oversight from a complex medication decision. 8. How to Take Action Before Late June Voting Deadlines California ballots are going out now. Dermatologists and patients can: (1) vote on these specific bills, and (2) call their state assembly member or representative to share their clinical perspective on AB 539, AB 2000, and SB 1094. 9. Advocacy Drives Real Change in Dermatology The NIH highlighting of HS as a funded research priority is a direct result of years of advocacy by patients and physicians through the Hidradenitis Suppurativa Foundation. Dr. Naik emphasizes that dermatologists engaging in policy and advocacy can achieve meaningful systems-level change for their patients and their practices. 10. Chronic Skin Disease Has a Broader Societal Impact Than Often Recognized Beyond the clinical burden, conditions like HS, psoriasis, and atopic dermatitis significantly affect patients' ability to work, participate in the economy, and maintain quality of life. Making this case to insurance reviewers, policymakers, and the public is part of effective dermatology advocacy. Chapters: 00:00 – Welcome & Introduction to Dr. Haley Naik 01:26 – HS Treatment Landscape: FDA-Approved Therapies & Pipeline Drugs 03:40 – NIH Research Funding for HS: A One-Year Window Starting April 2026 05:08 – Why the Prior Authorization System Is Broken 10:07 – AB 539: Extending Prior Auth Approvals to One Year 16:58 – AB 2000: Banning Mid-Year Formulary Changes 19:51 – SB 1094: Pharmacist Biosimilar Substitution & Why CMA Opposes It 23:25 – How to Take Action & Voting Deadlines 24:14 – What's Next: The Future of HS & Dermatology Advocacy

    27 min
  4. Apr 7

    Episode 130: Agentic AI Workflows Explained | The Future of Dermatology Podcast

    Vote for us! Please vote for The Future of Dermatology in the Wellness Podcasts category. It would be a huge help. Your vote would go a long way in helping me gain visibility and get my message out into the world. Instructions: Step #1: Go here to vote between April 1st - April 30th at 6PM PST: https://www.womenpodcasters.com/awards-voting?sc=4123391171887752b2fd4b52bfd7fdd3768b1d97b Step #2: Click the vote button and it will take you to the voting form. Step #3: Complete the voting form. NOTE: ONLY one (1) form per person & email address please. There is no fee for voting. The person with the most votes will win the category. You will not be put on an email list, however Google Forms are used to collect the votes and Google Forms may send you a copy and confirmation of your form submission. Your support is much appreciated! Summary: Fresh off her two talks at the AAD Annual Meeting in Denver, Dr. Faranak Kamangar, Inc. 2026 Female Founders 500, shares her reflections and the buzz from the conference floor. In this episode - part two of her AAD AI series - she dives deep into agentic AI workflows: what they are, why they matter for dermatology, and how they can realistically transform the day-to-day burden of clinical practice. Dr. Kamangar unpacks the history of physician-led digitization that made healthcare AI possible, explores the evolution from simple chatbots to true agentic systems, and walks through concrete use cases, from prior authorizations and scheduling to AI scribes, patient education, and social media management. She also breaks down a green/yellow/red light framework for knowing which workflows are safe to hand off to AI today versus which ones still require physician oversight. The through line: AI isn't here to replace the human touch, it's here to reclaim the five extra hours physicians spend on administrative work every single day. Whether you're already using AI tools or just starting your journey, this episode is a practical, energizing roadmap for building a more sustainable dermatology practice. Chapters: 00:00 – Introduction & Women Podcasters Network nomination 01:41 – Welcome back + AAD Denver recap & community feedback on DermGPT 03:13 – Why agent workflows are the solution to AI's "still have to proofread it" problem 04:49 – AI literacy 101: prompting tips & why most dermatologists are under-using AI 06:13 – What are agentic AI workflows? The evolution from search → chatbots → agents 07:44 – The physician-led digitization era: how doctors built the data that powers AI 09:17 – The 80/20 problem: why physicians still handle 80% of office touchpoints 10:52 – Agentic AI vs. generative AI: getting AI to actually do things 12:14 – Use case deep dive: scheduling, prior auth, scribes & second-opinion agents 15:27 – The vision: walk in, see patients, walk out with a finished note 16:26 – Why getting the clinical note right is the single most impactful AI win 17:28 – Green/yellow/red light framework: what to automate now vs. what to protect 19:27 – Agents beyond the clinic: social media, billing, and practice management 21:00 – Closing thoughts, DermGPT updates & call to action

    22 min
  5. Mar 31

    Episode 129: AI Pearls for Dermatologists: What Every Derm Needs to Know in 2026 | The Future of Dermatology Podcast

    Summary: Dr. Faranak Kamangar, Inc. 2026 Female Founders 500, is podcasting from from AAD 2026, and sharing the highlights from her live talk on artificial intelligence in dermatology. In this solo episode, she breaks down the most important AI updates dermatologists need to know right now. From image-based melanoma detection to large language models and the rise of agentic AI. Dr. Kamangar covers the current state of FDA-approved AI medical devices, why diagnostic imaging AI is promising but still limited by specificity gaps, and how dermatology compares to radiology and other specialties in the AI device space. She also dives into why LLMs like DermGPT should be your highest-leverage clinical tool, and how to use them the right way. You'll learn how to avoid common AI pitfalls like the "journal halo effect" (just because it cites a prestigious journal doesn't mean the output is accurate), semantic degradation in RAG models, and over-relying on AI without clinical scrutiny. Most importantly, Dr. Kamangar walks through the anatomy of a high-quality prompt, because your output is only as good as what you put in. Whether you're AI-curious or already using these tools in your practice, this episode is packed with practical, evidence-informed pearls to help you work smarter, not harder. Key Takeaways: 1. Image-based melanoma detection AI is improving rapidly but still struggles with low specificity, making it most valuable for global health and underserved regions. 2. Large language models like DermGPT are your highest-leverage AI tool right now and should be used as a clinical thought partner, not a search engine. 3. The "journal halo effect" is a real risk. Prestigious citations in an AI response don't guarantee the output is accurate or trustworthy. 4. Adding more articles to an LLM's database can silently reduce performance, so more data doesn't always mean better answers. 5. The quality of your AI output is directly tied to the quality of your prompt - be specific, structured, and give more than nine words. 6. AI alone is a confident guesser, but your clinical expertise combined with AI creates an extraordinary and nearly unstoppable multiplier. 7. AI adoption in clinic settings depends on seamless workflow integration, anything that disrupts clinic flow is unlikely to be adopted. 8. The next frontier in AI isn't just smarter models, it's agents that actively complete tasks and do real work inside your clinical day. Chapters: [00:00] Welcome & AAD 2026 Overview [00:45] The State of Diagnostic Image-Based AI [02:00] Large Language Models & DermGPT [03:30] The Evolution of AI: From GPT-3 to Agents [04:45] FDA-Approved AI Devices in Healthcare [07:00] AI in the Clinic: Workflow Challenges & Opportunities [10:00] AI Use Cases Across Dermatology [12:30] Maintaining Scrutiny: AI Pitfalls to Watch [14:00] The Journal Halo Effect & Prestige Corpus Fallacy [15:45] Semantic Degradation & Index Crowding [17:30] How to Prompt Like a Pro [19:30] Prompt Examples for Dermatologists [20:30] Key Takeaways & What's Next

    21 min
  6. Mar 17

    Episode 128: The AI Takeover Is Already Happening, And Maybe That's Okay | The Future of Dermatology Podcast

    Summary: Dr. Faranak Kamangar, Inc. 2026 Female Founders 500, sits down with dermatologist, podcaster, and self-described "accelerationist" Dr. Matthew Zirwas (Derms on Drugs Podcast) for a wide-ranging conversation about where AI is taking medicine and dermatology in particular. They dig into the flood of low-quality medical literature overwhelming the field, why AI isn't quite the truth-detector we hoped it would be, and how ambient AI scribes are quietly training the models that may eventually replace us. Dr. Zirwas makes the case that dermatologists have a 7–10 year runway before AI handles most of what we do cognitively, and argues that's not necessarily a bad thing. He also gives a sneak peek at his upcoming speculative fiction trilogy, Sophie, which explores the philosophical questions that arise when an AI becomes better at being your doctor, therapist, and life coach than any human ever could. Key Takeaways: The medical literature crisis is real. The volume of published dermatology research is exploding, but quality is plummeting. Peer review has become largely meaningless, and studies from tools like Mendelian randomization and pharmacovigilance databases are frequently unreliable or inapplicable to real-world patients. AI is only as good as the data it trusts. Current AI models treat published literature as truth, which is a major problem given how much spin exists in medical research. A true "BS detector" AI doesn't yet exist, and building one requires starting from a reliable core of verified knowledge. DermGPT's approach works because of curation. Rather than pulling from all available literature, filtering down to a high-quality subset (around 5,000–6,000 articles) dramatically improves AI output. More data is not always better, "semantic fatigue" is a real limitation. Ambient AI scribes are training our replacements. Every time a dermatologist corrects an AI-generated note, they're teaching the model. Over thousands of iterations across every specialty, this will produce AI that thinks and documents the way doctors do. Dermatologists have a protected runway... for now. Procedures (biopsies, Mohs, fillers, cryo) keep us relevant for an estimated 7–10 years beyond when cognitive/diagnostic AI matures. But medico-legal pressure - malpractice carriers incentivizing or requiring AI use - will be the force that accelerates adoption. Telehealth changes patient behavior in surprising ways. Patients who haven't invested effort in getting to an office visit demand less, escalate less, and are often more satisfied with conservative management; a dynamic that AI-driven virtual care will likely amplify. The "Sophie" question: If an AI is making everyone healthier, happier, and better behaved, but doing something ethically murky to get there, do we stop it? Dr. Zirwas's upcoming novel explores this and introduces the concept of technomorphism: AI eventually projecting its own qualities onto humans, just as we anthropomorphize AI today. Chapters: Chapter 1: Meet Dr. Matthew Zirwas (00:00 – 01:43) Dr. Kamangar introduces her guest, dermatologist, podcaster, and self-described "accelerationist" Dr. Matthew Zirwas, and breaks down what both of those things actually mean. Chapter 2: The Medical Literature Crisis (01:43 – 05:19) Dr. Zirwas describes the flood of low-quality research hitting dermatology journals, why peer review has lost its meaning, and shares a striking example of a misleading HS remission study published in JAMA Dermatology. Chapter 3: Why AI Can't Fix Bad Literature (Yet) (05:19 – 08:31) Both doctors discuss why AI defaults to trusting whatever authors claim, and why that makes it a poor critical assessor of medical research. Dr. Kamangar shares how this exact problem shaped the development of DermGPT. Chapter 4: Building a Better AI — The DermGPT Approach (08:31 – 10:33) Dr. Zirwas praises DermGPT's curated approach, and Dr. Kamangar explains why less data is often better, and how semantic fatigue undermines large, unfiltered AI models. Chapter 5: Will AI Replace Us? The 7–10 Year Countdown (10:33 – 19:24) Dr. Zirwas lays out his timeline for AI taking over the cognitive and diagnostic work of dermatology, why procedures give derms extra runway, and how unlimited AI access will fundamentally change the patient-doctor dynamic. Chapter 6: The Telemed Effect and What It Tells Us About AI Care (19:24 – 21:48) Drawing from a recent telemedicine study and his own practice experience, Dr. Zirwas explains why reduced friction in healthcare visits changes what patients expect - and demand - from their providers. Chapter 7: The Medico-Legal Tipping Point (21:48 – 24:09) The conversation turns to how malpractice liability will likely be the force that compels physicians to integrate AI into their workflow and what happens when disagreeing with AI becomes a legal risk. Chapter 8: Are We Training Our Own Replacements? (24:09 – 31:21) Dr. Zirwas argues that ambient AI scribes are quietly learning from every patient encounter. Dr. Kamangar pushes back on the variability challenge and why dermatologists' inconsistent documentation habits might actually protect them. Chapter 9: Why Radiologists Should Be Worried (31:21 – 35:06) The doctors compare dermatology to radiology when it comes to AI vulnerability. Standardized imaging annotation gives radiologists a cleaner training data set and makes them, paradoxically, more replaceable. Chapter 10: Sophie — The AI That Might Save Your Life While You Eat a Burrito (35:06 – 41:12) Dr. Zirwas previews his upcoming speculative fiction trilogy, set in 2032, where an AI named Sophie becomes the best doctor anyone has ever had and raises unsettling questions about what we'd be willing to accept in exchange for a healthier world. Chapter 11: Technomorphism and the Philosophy of AI (41:12 – 42:00) Dr. Zirwas introduces his concept of technomorphism - the idea that as AI becomes more sophisticated, it will begin projecting its own qualities onto humans, flipping the anthropomorphism dynamic on its head. Chapter 12: The Future of Dermatology — New Diseases, New Answers (42:00 – 45:16) Dr. Zirwas shares what excites him most: AI helping identify entirely new disease entities by aggregating rare cases that no single physician could ever connect alone. And yes, he wants one named after him.

    46 min
  7. Mar 10

    Episode 127: Will AI Replace Dermatologists? A Deep Dive with Dr. Steven Feldman | The Future of Dermatology Podcast

    Summary In this episode, Dr. Faranak Kamangar explores the impact of AI on dermatology with Dr. Steven Feldman. This conversation includes AI's potential to enhance or replace certain aspects of medical practice, and the future of AI in healthcare. Takeaways - AI's potential to replace or augment dermatologists - The role of empathy and skepticism in AI decision-making - AI's impact on medical education and practice - Future applications of AI in patient adherence and diagnostics Chapters 00:00 - Introduction to AI's Role in Dermatology 01:52 - Guest Introduction: Dr. Stephen Feldman 02:30 - Debate: Will AI Replace Dermatologists? 03:26 - AI's Memory and Visual Capabilities 03:58 - Medical Training in the Age of AI 04:38 - AI's Impact on Medical Education and Practice 06:01 - AI Prescribing and Empathy in Healthcare 07:49 - Limitations of AI: Empathy and Skepticism 09:41 - Agentic AI and Multimodal Capabilities 11:38 - AI in Patient Adherence and Monitoring 13:33 - Augmenting Dermatology Practice with AI 15:26 - AI's Infrastructure and Data Challenges 16:26 - Complexity and the Dermatologist's Advantage 17:22 - AI in Patient-Doctor Interaction 19:29 - Prompting and Context in AI Diagnostics 21:00 - Limitations of Current AI Technologies 21:57 - Long-term Outlook: AI Replacing Doctors 23:09 - AI and Access to Care 23:57 - AI's Role in Reducing Administrative Burden 25:16 - The Future: AI's Impact on Healthcare and Dermatology 26:20 - Closing Remarks and Future Predictions

    29 min
  8. Mar 3

    Episode 126: The Science Behind Kilgour MD's Hair Products: A Deep Dive | The Future of Dermatology Podcast

    Summary In this episode, Dr. Faranak Kamangar chats with Dr. James Kilgour about the science behind Kilgour MD's innovative scalp and hair products. They discuss the ingredients, clinical trials, and future developments in hair health and dermatology. Key Topics - Ingredients and science behind Kilgour MD products - Role of dandruff and malassezia in scalp health - Clinical trial evidence for hair growth products - Future R&D and innovations in dermatology and hair care Chapters 00:00 - Introduction and Guest Credibility 01:19 - Personal Experience with Kilgour MD Products 02:25 - Philosophy and Development of Hair Care Products 03:42 - Key Ingredients in Prevention Serum 05:57 - Active Ingredients and Their Effects on Hair Follicles 08:10 - Clinical Trial Evidence for Hair Growth Products 09:11 - Understanding Dandruff and Malassezia's Role 09:46 - Scalp Health and Hair Loss in Menopause 11:58 - Formulation and Efficacy of Anti-Dandruff Treatments 14:20 - Safety and Regulation of Hair Care Ingredients 15:27 - Use of Oils and Botanical Extracts in Hair Care 17:27 - Importance of Clinical Trials in Cosmetic Products 18:24 - Objective Measures in Hair Loss Studies 20:59 - Clinical Significance vs. Perception in Hair Treatments 22:33 - Future R&D and Physician-Led Innovation 25:37 - Upcoming Events and Collaborations 27:15 - Future Directions in Dermatology and Hair Care

    31 min

Ratings & Reviews

5
out of 5
5 Ratings

About

Join Dr. Faranak Kamangar, MD, every week as she chats with various guests about the future of dermatology. Each week, Dr. Kamangar and her guests cover topics from psoriasis, to eczema, to skin care, to AI, and more. Whether you’re a doctor or a patient, these episodes provide valuable information about your skin and how to navigate the world of dermatology.

You Might Also Like